These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33658646)

  • 1. Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies.
    Shimomura Y; Hara M; Yamamoto H; Uchida N; Kawakita T; Ashida T; Takada S; Ikeda T; Morishige S; Maruyama Y; Wake A; Ichinohe T; Fukuda T; Takanashi M; Atsuta Y; Ishikawa T
    Bone Marrow Transplant; 2021 Jul; 56(7):1691-1699. PubMed ID: 33658646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloablative Versus Reduced-Intensity Conditioning With Fludarabine/Busulfan for Myelodysplastic Syndrome: A Propensity Score-Matched Analysis.
    Kurosawa S; Shimomura Y; Itonaga H; Najima Y; Kobayashi T; Ozawa Y; Kanda Y; Kako S; Kawakita T; Matsuoka KI; Maruyama Y; Ota S; Nakazawa H; Imada K; Kimura T; Kanda J; Fukuda T; Atsuta Y; Ishiyama K
    Transplant Cell Ther; 2022 Jun; 28(6):323.e1-323.e9. PubMed ID: 35296446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation.
    Kamijo K; Shimomura Y; Shinohara A; Mizuno S; Kanaya M; Usui Y; Kim SW; Ara T; Mizuno I; Kuriyama T; Nakazawa H; Matsuoka KI; Kusumoto S; Maseki N; Yamaguchi M; Ashida T; Onizuka M; Fukuda T; Atsuta Y; Kondo E
    Ann Hematol; 2023 Mar; 102(3):651-661. PubMed ID: 36631705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis.
    Kurosawa S; Shimomura Y; Itonaga H; Najima Y; Kobayashi T; Ozawa Y; Kanda Y; Kako S; Kawakita T; Matsuoka KI; Maruyama Y; Ota S; Nakazawa H; Imada K; Kanda J; Fukuda T; Atsuta Y; Aoki J
    Bone Marrow Transplant; 2021 Dec; 56(12):3008-3015. PubMed ID: 34489555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation.
    Ueda T; Maeda T; Kusakabe S; Fujita J; Fukushima K; Yokota T; Shibayama H; Tomiyama Y; Kanakura Y
    Int J Hematol; 2019 Feb; 109(2):197-205. PubMed ID: 30448938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable Outcome with Conditioning Regimen of Flu/Bu4/Mel in Acute Myeloid Leukemia Patients in Remission Undergoing Cord Blood Transplantation.
    Mizuno S; Takami A; Kawamura K; Shimomura Y; Arai Y; Konuma T; Ozawa Y; Sawa M; Ota S; Takahashi S; Anzai N; Hiramoto N; Onizuka M; Nakamae H; Tanaka M; Murata M; Kimura T; Kanda J; Fukuda T; Atsuta Y; Yanada M
    Transplant Cell Ther; 2022 Nov; 28(11):775.e1-775.e9. PubMed ID: 35921987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fludarabine Melphalan, Reduced-dose Busulfan Versus Fludarabine, Melphalan, Full-dose Busulfan in Patients Receiving Cord Blood Transplantation.
    Arai N; Narita H; Kuroiwa K; Nagao K; Hayashi H; Kawamata N; Okamura R; Sasaki Y; Shimada S; Watanuki M; Kawaguchi Y; Yanagisawa K; Hattori N
    Transplant Proc; 2024 Oct; 56(8):1828-1835. PubMed ID: 39232926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia.
    DiMaggio E; Zhou JM; Caddell R; Tombleson R; Perkins J; Anasetti C; Khimani F; Pidala J; Nishihori T; Perez L; Betts B; Fernandez HF; Mishra A
    Leuk Lymphoma; 2020 Jul; 61(7):1678-1687. PubMed ID: 32133897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low Incidence of Relapse with a Moderate Conditioning Regimen of Fludarabine, Busulfan, and Melphalan for Patients with Myeloid Malignancies: A Single-Center Analysis of 100 Patients.
    Jiang JL; Gao WH; Wang LN; Wan M; Wang L; Hu J
    Transplant Cell Ther; 2023 Aug; 29(8):512.e1-512.e8. PubMed ID: 37263418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan.
    Yamashita T; Takami A; Uchida N; Fukuda T; Eto T; Shiratori S; Ota S; Akasaka T; Miyakoshi S; Kondo T; Hidaka M; Kanda J; Atsuta Y; Yano S
    Bone Marrow Transplant; 2020 Oct; 55(10):1955-1965. PubMed ID: 32203256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curative potential of fludarabine, melphalan, and non-myeloablative dosage of busulfan in elderly patients with myeloid malignancy.
    Ueda T; Jo T; Okada K; Arai Y; Sato T; Maeda T; Onishi T; Ueda Y
    Int J Hematol; 2020 Feb; 111(2):247-255. PubMed ID: 31701479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity.
    Bartelink IH; van Reij EM; Gerhardt CE; van Maarseveen EM; de Wildt A; Versluys B; Lindemans CA; Bierings MB; Boelens JJ
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):345-53. PubMed ID: 24315842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
    Dhere V; Edelman S; Waller EK; Langston A; Graiser M; Connolly EC; Switchenko JM; Esiashvili N; Khan MK
    Leuk Lymphoma; 2018 Apr; 59(4):837-843. PubMed ID: 28782395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
    Ishida H; Adachi S; Hasegawa D; Okamoto Y; Goto H; Inagaki J; Inoue M; Koh K; Yabe H; Kawa K; Kato K; Atsuta Y; Kudo K
    Pediatr Blood Cancer; 2015 May; 62(5):883-9. PubMed ID: 25545836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
    Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
    Spitzer B; Jakubowski AA; Papadopoulos EB; Fuller K; Hilden PD; Young JW; Barker JN; Koehne G; Perales MA; Hsu KC; van den Brink MR; Kernan NA; Prockop SE; Scaradavou A; Castro-Malaspina H; O'Reilly RJ; Boulad F
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2088-2095. PubMed ID: 28711727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Allogeneic stem cell transplantation with fludarabine/melphalan (non-TBI and non-BU/CY) for patients aged 50 or more].
    Inamoto Y; Kuwatsuka Y; Tsujimura A; Tokunaga M; Oba T; Miyamura K; Kodera Y
    Rinsho Ketsueki; 2006 Jan; 47(1):9-15. PubMed ID: 16479977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Different Fludarabine Doses in the Fludarabine-Based Conditioning Regimen for Unrelated Bone Marrow Transplantation.
    Kuriyama K; Fuji S; Ito A; Doki N; Katayama Y; Ohigashi H; Nishida T; Serizawa K; Eto T; Uchida N; Kanda Y; Tanaka M; Matsuoka KI; Nakazawa H; Kanda J; Fukuda T; Atsuta Y; Ogata M
    Transplant Cell Ther; 2024 May; 30(5):514.e1-514.e13. PubMed ID: 38373522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders.
    Marsh RA; Hebert K; Kim S; Dvorak CC; Aquino VM; Baker KS; Chellapandian D; Dávila Saldaña B; Duncan CN; Eckrich MJ; Georges GE; Olson TS; Pulsipher MA; Shenoy S; Stenger E; Lugt MV; Yu LC; Gennery AR; Eapen M
    J Allergy Clin Immunol; 2022 Mar; 149(3):1097-1104.e2. PubMed ID: 34375618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity.
    Eapen M; Brazauskas R; Hemmer M; Perez WS; Steinert P; Horowitz MM; Deeg HJ
    Blood Adv; 2018 Aug; 2(16):2095-2103. PubMed ID: 30135184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.